PCG
IOVA icon

Private Capital Group’s Iovance Biotherapeutics IOVA Stock Holding History

Private Capital Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-53
Closed -$1K – 2179
2021
Q2 		$1K Buy
+53
New +$1.38K ﹤0.01% 1974

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Private Capital Group's IOVA Position: Q3 2021 in Review

Private Capital Group sold out of Iovance Biotherapeutics (IOVA) in Q3 2021, closing a stake of 53 shares — an estimated $1K sold.

Private Capital Group first reported a position in IOVA in Q2 2021 and held it in 1 quarter. The position peaked at $1K in Q2 2021. 243 funds tracked by Wall St. Rank hold IOVA as of Q3 2021.

  • Private Capital Group reported no remaining Iovance Biotherapeutics position as of Q3 2021 after selling out during the quarter.
  • Private Capital Group sold 53 Iovance Biotherapeutics shares in Q3 2021, an estimated $1K.
  • Private Capital Group first reported a position in Iovance Biotherapeutics in Q2 2021 and held it in 1 quarter.
  • Private Capital Group's Iovance Biotherapeutics position peaked at $1K in Q2 2021.
  • 243 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2021.

Based on Private Capital Group's 13F filing for Q3 2021, filed 13 Oct 2021.